evaluation of thyroid dysfunction during imatinib therapy in chronic myeloid leukemia

Authors

abolghasem allahyari department of hematology-oncology, emam reza hospital, school of medicine, mashhad university of medical sciences, mashhad, iranسازمان اصلی تایید شده: دانشگاه علوم پزشکی مشهد (mashhad university of medical sciences)

foroogh salehi department of endocrinology, vali asr hospital, school of medicine, birjand university of medical sciences, birjand, iranسازمان اصلی تایید شده: دانشگاه علوم پزشکی بیرجند (birjand university of medical sciences)

mostafa kaboli department of internal medicine, school of medicine, birjand university of medical sciences, birjand, iranسازمان اصلی تایید شده: دانشگاه علوم پزشکی بیرجند (birjand university of medical sciences)

masoud sadeghi cancer research center, kermanshah university of medical sciences, kermanshah, iranسازمان اصلی تایید شده: دانشگاه علوم پزشکی کرمانشاه (kermanshah university of medical sciences)

abstract

background: imatinib mesylate is the first generation of tyrosine kinase inhibitors (tki) and highly effective in the treatment of chronic myeloid leukemia (cml). we aimed to evaluate thyroid function at baseline and at 1, 3, 6 and 12 months after initiation of imatinib mesylate therapy in 20 newly diagnosed bcr-abl positive cml patients. methods: this study was done during 2013-2014, 20 new cases with philadelphia chromosome-positive cml without any underlying thyroid disorder or drug history interfering with imatinib mesylate were enrolled. thyroid function tests including serum thyroid-stimulating hormone (tsh), free thyroxine (ft4), free triiodothyronine (ft3), anti-thyroid peroxidase (anti-tpo) and anti-thyroglobulin (anti-tg) were assessed at baseline and during follow-up. results: mean age at diagnosis was 60.4 years. 14 (70%) patients were male.  mean value for tsh, ft4, ft3, anti-tpo, and anti-tg before treatment were 2.82 miu/l, 1.39 ng/dl, 325.50 ng/dl, 30.35 iu/ml and 39.40 iu/ml, respectively. the mean value for tsh, ft4, ft3 and anti-tpo 1, 3, 6, and 12 months after initiation of imatinib mesylate were not statistically significant. conclusion: based on the results of the study, there was no significant change in thyroid function tests during treatment with imatinib mesylate and all laboratory variables were in normal ranges.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

Evaluation of Thyroid Dysfunction during Imatinib Therapy in Chronic Myeloid Leukemia

Background: Imatinib mesylate is the first generation of Tyrosine kinase inhibitors (TKI) and highly effective in the treatment of chronic myeloid leukemia (CML). We aimed to evaluate thyroid function at baseline and at 1, 3, 6 and 12 months after initiation of Imatinib mesylate therapy in 20 newly diagnosed BCR-ABL positive CML patients. Methods: This study was done during 2013-2014, 20 new c...

full text

imatinib therapy in chronic myelogenous leukemia and thyroid function tests.

introduction: imatinib, a tyrosine kinase inhibitor which resulted in much improvement in the treatment of chronic myelogenous leukemia (cml), may adversely affect thyroid gland function. to date, assessment of thyroid function during imatinib therapy has limited to retrospective studies. the aim of this study was to evaluate the effects of imatinib on thyroid function in a prospective manner. ...

full text

Analysis of Expression Of SIRT1 Gene In Patients With Chronic Myeloid Leukemia Resistant To Imatinib Mesylate

Background: Chronic myeloid leukemia is a clonal myeloproliferative disease which is characterized by bcr/abl translocation. With the emergence of tyrosine kinase inhibitors such as imatinib mesylate, significant improvement has been made in treatment of this disease. However, drug resistance against this medicine is still an obstacle. SIRT1 is a gene with deacetylase activity which has been de...

full text

Therapy of Chronic Myeloid Leukemia: Twilight of the Imatinib Era?

Chronic myeloid leukemia (CML) results from the clonal expansion of pluripotent hematopoietic stem cells containing the active BCR/ABL fusion gene produced by a reciprocal translocation of the ABL1 gene to the BCR gene. The BCR/ABL protein displays a constitutive tyrosine kinase activity and confers on leukemic cells growth and proliferation advantage and resistance to apoptosis. Introduction o...

full text

Promyelocytic Blastic Crisis in Chronic Myeloid Leukemia During Imatinib Treatment

Figure 1. Leukemic cell morphology of bone marrow aspiration specimen (May-Grünwald-Giemsa). An 82-year-old woman was admitted to our hospital presenting with febrile neutropenia. She had been diagnosed with chronic myeloid leukemia 2 years ago and had been on imatinib treatment since [1]. A month before admission she presented with malaise, anemia, and mild leukopenia; a bone marrow aspirate a...

full text

Imatinib Therapy in Chronic Myelogenous Leukemia and Thyroid Function Tests

INTRODUCTION Imatinib, a tyrosine kinase inhibitor which resulted in much improvement in the treatment of chronic myelogenous leukemia (CML), may adversely affect thyroid gland function. To date, assessment of thyroid function during imatinib therapy has limited to retrospective studies. The aim of this study was to evaluate the effects of imatinib on thyroid function in a prospective manner. ...

full text

My Resources

Save resource for easier access later


Journal title:
iranian journal of blood and cancer

جلد ۸، شماره ۱، صفحات ۹-۱۲

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023